CN108836997A - 一种用于癌症康复治疗的药物及制备方法 - Google Patents
一种用于癌症康复治疗的药物及制备方法 Download PDFInfo
- Publication number
- CN108836997A CN108836997A CN201811012826.4A CN201811012826A CN108836997A CN 108836997 A CN108836997 A CN 108836997A CN 201811012826 A CN201811012826 A CN 201811012826A CN 108836997 A CN108836997 A CN 108836997A
- Authority
- CN
- China
- Prior art keywords
- cancer
- pharmaceutical composition
- rehabilitation treatment
- preparation
- kuh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 83
- 201000011510 cancer Diseases 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 229940079593 drug Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 29
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 24
- 230000036039 immunity Effects 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 238000012869 ethanol precipitation Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- -1 oral solution Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000000840 anti-viral effect Effects 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 231100000614 poison Toxicity 0.000 abstract description 5
- 239000003440 toxic substance Substances 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229930017327 cytisine Natural products 0.000 description 1
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 1
- 229940027564 cytisine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种用于癌症康复治疗的药物组合物及制备方法,属于癌症治疗药物技术领域。所述药物组合物的组分包括西洋参、苦参、甘草精粉,所述西洋参、苦参、甘草精粉的重量比为0.5‑1.5:0.5‑1.5:0.5‑1.5,优选为重量比1:1:1的西洋参、苦参、甘草精粉为原料,经提取、过滤、滤液浓缩成浸膏并混合而得;具有补气补血,养阴清热、解毒杀虫,促免疫,抗病毒,调平衡的功效,用于癌症的康复治疗,可以提高癌症的治愈率和康复率;同时可在制备癌症辅助康复药物、制备提高个体免疫力的药物及制备辅助治疗肿瘤的药物中应用;其成本相对低廉,降低患者经济压力,适合推广使用。
Description
技术领域
本发明涉及癌症治疗药物技术领域,具体的涉及一种用于癌症康复治疗的药物及制备方法。
背景技术
在医学上,癌是指起源于上皮组织的恶性肿瘤,是恶性肿瘤中最常见的一类。相对应的,起源于间叶组织的恶性肿瘤统称为肉瘤。有少数恶性肿瘤不按上述原则命名,如肾母细胞瘤、恶性畸胎瘤等。一般人们所说的“癌症”习惯上泛指所有恶性肿瘤。
在研究肿瘤和癌症的发生基本原理中得出,肿瘤人体内分泌激素正常或低下,恰遇癌病毒感染,T细胞和B细胞功能轻度不足,可以产生人体树突细胞,细胞代谢为有氧代谢,细胞常为有性繁殖,细胞常呈膨胀性生长,细胞生长缓慢,常不影响机体的功能和生命;而癌症的人体内分泌激素低下或严重不足,恰遇癌病毒感染,人体T细胞和B细胞功能严重不足或丧失,不产生树突细胞,细胞常为无氧代谢,多为无性繁殖,细胞呈增殖性无系侵润型生长。癌症病情发展快,细胞及组织增生成肿块,压迫附近组织和器官,侵犯人体组织和器官,使其丧失功能。
所以中医治疗肿瘤(癌症)的基本原则:补气补血,调和营卫、清热解毒,活血化瘀、软坚散结,去淤生新,回阳救逆;所以及时提高人体的免疫功能是促进癌症康复治疗的关键。
发明内容
针对现有技术存在的上述问题,本发明提供了一种用于癌症康复治疗的药物及制备方法,具有补气补血,养阴清热、解毒杀虫,促免疫,抗病毒,调平衡的功效,用于癌症的康复治疗,可以提高癌症的治愈率和康复率。
为实现上述技术目的,达到上述技术效果,本发明是通过以下技术方案实现:
一种用于癌症康复治疗的药物组合物,所述药物组合物的组分包括西洋参、苦参、甘草精粉,所述西洋参、苦参、甘草精粉的重量比为0.5-1.5:0.5-1.5:0.5-1.5。
一种用于癌症康复治疗的药物组合物,包括重量比1:1:1的西洋参、苦参、甘草精粉。
本发明的另一目的在于提供一种用于癌症康复治疗的药物组合物的制备方法,所述癌症康复治疗的药物组合物的制备方法包括以下步骤:
步骤一、取西洋参,加NaHCO3溶液提取,提取液加乙醇沉淀,静置,过滤,滤液浓缩回收乙醇,浓缩成浸膏;
步骤二、取等量苦参加稀盐酸渗漉,渗漉液过树脂,树脂用水洗脱,氨水碱化后采用醇洗脱,洗脱液回收醇,浓缩成浸膏;
步骤三、取等量的甘草精粉加水提取,过滤,滤液浓缩成浸膏与步骤一、二所得产物混合均匀,直接或加入药学上可接受的辅料,制成片剂、口含片剂、口服液、颗粒剂、胶囊或散剂,在常温下无菌保存。
进一步的,所述辅料为乳化剂、粘合剂、填充剂、压片剂、稀释剂、润湿剂、崩解剂、着色剂、调味剂、润湿剂或其他药用载体材料。
本发明所述的癌症康复治疗的药物组合物可采用等量的成分通过煎煮法、浸渍法、渗漉法、回流法、水提醇沉、醇提水沉等方法制备而得。
本发明所述的癌症康复治疗的药物组合物可提取为皂甙或小分子制剂。
进一步的,所述癌症康复治疗的药物组合物在制备癌症辅助康复药物中的用途。
进一步的,所述癌症康复治疗的药物组合物在在制备提高个体免疫力的药物中的用途。
进一步的,所述癌症康复治疗的药物组合物在制备辅助治疗肿瘤的药物中的用途。
本发明的有益效果是:本发明癌症康复治疗的药物采用重量比为 0.5-1.5:0.5-1.5:0.5-1.5的西洋参、苦参、甘草精粉经提取、过滤、滤液浓缩成浸膏并混合而得;具有补气补血,养阴清热、解毒杀虫,促免疫,抗病毒,调平衡的功效,用于癌症的康复治疗,可以提高癌症的治愈率和康复率;同时可在制备癌症辅助康复药物、制备提高个体免疫力的药物及制备辅助治疗肿瘤的药物中应用;其成本相对低廉,降低患者经济压力,适合推广使用。
当然,实施本发明的任一产品并不一定需要同时达到以上所述的所有优点。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明实施例所述癌症康复治疗的药物组合物的制备方法流程图;
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1
一种用于癌症康复治疗的药物组合物,所述药物组合物的组分包括西洋参、苦参、甘草精粉,所述西洋参、苦参、甘草精粉的重量比为0.5-1.5:0.5-1.5:0.5-1.5。
一种用于癌症康复治疗的药物组合物,包括重量比1:1:1的西洋参、苦参、甘草精粉。
如图1所示,本发明的另一目的在于提供一种用于癌症康复治疗的药物组合物的制备方法,所述癌症康复治疗的药物组合物的制备方法包括以下步骤:
步骤一、取西洋参,加NaHCO3溶液提取,提取液加乙醇沉淀,静置,过滤,滤液浓缩回收乙醇,浓缩成浸膏;
步骤二、取等量苦参加稀盐酸渗漉,渗漉液过树脂,树脂用水洗脱,氨水碱化后采用醇洗脱,洗脱液回收醇,浓缩成浸膏;
步骤三、取等量的甘草精粉加水提取,过滤,滤液浓缩成浸膏与步骤一、二所得产物混合均匀,直接或加入药学上可接受的辅料,制成片剂、口含片剂、口服液、颗粒剂、胶囊或散剂,在常温下无菌保存。
进一步的,所述辅料为乳化剂、粘合剂、填充剂、压片剂、稀释剂、润湿剂、崩解剂、着色剂、调味剂、润湿剂或其他药用载体材料。
本发明所述的癌症康复治疗的药物组合物可采用等量的成分通过煎煮法、浸渍法、渗漉法、回流法、水提醇沉、醇提水沉等方法制备而得。
本发明所述的癌症康复治疗的药物组合物可提取为皂甙或小分子制剂。
本发明药物组合物的组分中的西洋参、苦参、甘草精粉,其药理性为:
西洋参:
性味:性凉,味甘、微苦;
功能主治:补气养阴,清热生津。用于气虚阴亏,内热,咳喘痰血,虚热烦倦,消渴,口燥喉干。
具有较多的保健价值
增强中枢神经系统功能:西洋参中的皂甙可以有效增强中枢神经,达到静心凝神、消除疲劳、增强记忆力等作用,可适用于失眠、烦躁、记忆力衰退及老年痴呆等症状。
保护心血管系统:常服西洋参可以抗心律失常、抗心肌缺血、抗心肌氧化、强化心肌收缩能力,冠心病患者症状表现为气阴两虚、心慌气短可长期服用西洋参,疗效显著。西洋参的功效还在于可以调节血压,可有效降低暂时性和持久性血压,有助于高血压、心律失常、冠心病、急性心肌梗塞、脑血栓等疾病的恢复。
提高免疫力:西洋参作为补气保健首选药材,可以促进血清蛋白合成、骨髓蛋白合成、器官蛋白合成等,提高机体免疫力,抑制癌细胞生长,有效抵抗癌症。
促进血液活力:长服西洋参可以降低血液凝固性、抑制血小板凝聚、抗动脉粥样硬化并促进红血球生长,增加血色素。[4]
治疗糖尿病
补肺降火、养胃生津:西洋参性寒,味苦、微甘,归心、肺、肾经,具有补肺降火、养胃生津之功效。
苦参:
苦,寒,无毒
功能主治:心腹结气,症瘕积聚,黄胆,溺本经》。养肝胆气,安五脏,平胃气,令人嗜食轻身,定志益精,利九窍,除伏热肠,止渴醒酒,小便黄赤,疗恶疮、下部蚀《别录》。渍酒饮,治疥杀虫。治恶虫、胫酸。治热毒风,皮肌烦躁生疮,赤癞眉脱,除大热嗜睡,治腹中冷痛,中恶腹痛。杀疳虫。炒存性,米饮服,治肠风泻血并热痢《大明》。
根含苦参碱(matrine)和金雀花碱(cytisine)等,入药有清热利湿,抗菌消炎,健胃驱虫之效,常用作治疗皮肤瘙痒,神经衰弱,消化不良及便秘等症;
甘草精粉是一种甘草酸含量较高的甘草粉(重量法≥20%,液相色谱法≥8%),感观、性效类似甘草浸膏粉。它由甘草经清洗、切片、熬煮(提取)、静置(沉淀)、过滤、浓缩、干燥(烘干后粉碎或喷雾干燥法)制得。解决了甘草粉存在难溶物多,色泽细度不一,甘草酸含量低,质量不稳定等缺点。
本发明癌症康复治疗的药物采用重量比为0.5-1.5:0.5-1.5:0.5-1.5 的西洋参、苦参、甘草精粉经提取、过滤、滤液浓缩成浸膏并混合而得;具有补气补血,养阴清热、解毒杀虫,促免疫,抗病毒,调平衡的功效,用于癌症的康复治疗,可以提高癌症的治愈率和康复率;
上述癌症康复治疗的药物组合物在制备癌症辅助康复药物中的用途。
上述癌症康复治疗的药物组合物在在制备提高个体免疫力的药物中的用途。
上述癌症康复治疗的药物组合物在制备辅助治疗肿瘤的药物中的用途。
实施例2
如图1所示,癌症康复治疗的药物组合物的制备方法包括以下步骤:
步骤一、取西洋参,加NaHCO3溶液提取,提取液加乙醇沉淀,静置,过滤,滤液浓缩回收乙醇,浓缩成浸膏;
步骤二、取与步骤一所用西洋参等量苦参加稀盐酸渗漉,渗漉液过树脂,树脂用水洗脱,氨水碱化后采用醇洗脱,洗脱液回收醇,浓缩成浸膏;
步骤三、取等量的甘草精粉加水提取,过滤,滤液浓缩成浸膏与步骤一、二所得产物混合均匀,直接或加入药学上可接受的辅料,辅料为乳化剂、粘合剂、填充剂、压片剂、稀释剂、润湿剂、崩解剂、着色剂、调味剂、润湿剂或其他药用载体材料;
亦可以可采用等量的成分通过煎煮法、浸渍法、渗漉法、回流法、水提醇沉、醇提水沉等方法制备而得。
亦可以可提取为皂甙或小分子制剂。
基于上述药物组合物的基础上,癌症康复治疗的药物组合物在制备癌症辅助康复药物中的用途。
上述癌症康复治疗的药物组合物在在制备提高个体免疫力的药物中的用途。
上述癌症康复治疗的药物组合物在制备辅助治疗肿瘤的药物中的用途。
实施例3
按照上述实施例操作步骤制备“双参胶囊”胶囊剂,在常温下无菌保存;针对癌症患者,每次2粒(约1克量),一日三次,每月连服 20天为一疗程,可连服10个疗程,癌症晚期可延长服药时间,在大鼠模型和检测到癌症的患者服用治疗后,与设计的对照组相比具有较好的效果。
本发明癌症康复治疗的药物采用重量比为0.5-1.5:0.5-1.5:0.5-1.5 的西洋参、苦参、甘草精粉经提取、过滤、滤液浓缩成浸膏并混合而得;具有补气补血,养阴清热、解毒杀虫,促免疫,抗病毒,调平衡的功效,用于癌症的康复治疗,可以提高癌症的治愈率和康复率;同时可在制备癌症辅助康复药物、制备提高个体免疫力的药物及制备辅助治疗肿瘤的药物中应用;其成本相对低廉,降低患者经济压力,适合推广使用。
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (8)
1.一种用于癌症康复治疗的药物组合物,其特征在于:所述药物组合物的组分包括西洋参、苦参、甘草精粉,所述西洋参、苦参、甘草精粉的重量比为0.5-1.5:0.5-1.5:0.5-1.5。
2.如权利要求1所述的一种用于癌症康复治疗的药物组合物,其特征在于:其特征在于:包括重量比1:1:1的西洋参、苦参、甘草精粉。
3.一种如权利要求1或2任意一项所述的用于癌症康复治疗的药物组合物的制备方法,其特征在于:所述癌症康复治疗的药物组合物的制备方法包括以下步骤:
步骤一、取西洋参,加NaHCO3溶液提取,提取液加乙醇沉淀,静置,过滤,滤液浓缩回收乙醇,浓缩成浸膏;
步骤二、取等量苦参加稀盐酸渗漉,渗漉液过树脂,树脂用水洗脱,氨水碱化后采用醇洗脱,洗脱液回收醇,浓缩成浸膏;
步骤三、取等量的甘草精粉加水提取,过滤,滤液浓缩成浸膏与步骤一、二所得产物混合均匀,直接或加入药学上可接受的辅料,制成片剂、口含片剂、口服液、颗粒剂、胶囊或散剂,在常温下无菌保存。
4.如权利要求3所述的用于癌症康复治疗的药物组合物的制备方法,其特征在于:所述辅料为乳化剂、粘合剂、填充剂、压片剂、稀释剂、润湿剂、崩解剂、着色剂、调味剂、润湿剂或其他药用载体材料。
5.如权利要求3所述的用于癌症康复治疗的药物组合物的制备方法,其特征在于:所述的癌症康复治疗的药物组合物可提取为皂甙或小分子制剂。
6.一种如权利要求1所述的癌症康复治疗的药物组合物在制备癌症辅助康复药物中的用途。
7.一种如权利要求1所述的癌症康复治疗的药物组合物在在制备提高个体免疫力的药物中的用途。
8.一种如权利要求1所述的癌症康复治疗的药物组合物在制备辅助治疗肿瘤的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811012826.4A CN108836997A (zh) | 2018-08-31 | 2018-08-31 | 一种用于癌症康复治疗的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811012826.4A CN108836997A (zh) | 2018-08-31 | 2018-08-31 | 一种用于癌症康复治疗的药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108836997A true CN108836997A (zh) | 2018-11-20 |
Family
ID=64233929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811012826.4A Pending CN108836997A (zh) | 2018-08-31 | 2018-08-31 | 一种用于癌症康复治疗的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108836997A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101764A (zh) * | 2019-06-11 | 2019-08-09 | 武汉圣润生物科技有限公司 | 一种辅助肿瘤治疗的组合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312077A (zh) * | 2001-01-04 | 2001-09-12 | 贺平 | 甘草和苦参有效提取物组成的复方组份及其应用 |
CN101263887A (zh) * | 2008-05-08 | 2008-09-17 | 常德有为物资再生有限责任公司 | 喷雾干燥法制备甘草精粉的生产方法 |
CN101439082A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含苦参提取物的中药颗粒及其制备方法 |
CN105412522A (zh) * | 2015-12-03 | 2016-03-23 | 陕西易阳科技有限公司 | 一种升白口服液的制备方法 |
-
2018
- 2018-08-31 CN CN201811012826.4A patent/CN108836997A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312077A (zh) * | 2001-01-04 | 2001-09-12 | 贺平 | 甘草和苦参有效提取物组成的复方组份及其应用 |
CN101439082A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含苦参提取物的中药颗粒及其制备方法 |
CN101263887A (zh) * | 2008-05-08 | 2008-09-17 | 常德有为物资再生有限责任公司 | 喷雾干燥法制备甘草精粉的生产方法 |
CN105412522A (zh) * | 2015-12-03 | 2016-03-23 | 陕西易阳科技有限公司 | 一种升白口服液的制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101764A (zh) * | 2019-06-11 | 2019-08-09 | 武汉圣润生物科技有限公司 | 一种辅助肿瘤治疗的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN102784363A (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN104288461A (zh) | 参鹿茶中药饮片组合制剂、制备方法及组合包装 | |
CN104491342A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN103656403A (zh) | 一种治疗肺结核的中药组合物及其制备方法 | |
CN101011562A (zh) | 参芪温胆汤新剂型及其生产方法 | |
CN106173605A (zh) | 一种包含葛根和石斛的降血糖保健组合物 | |
CN103735843A (zh) | 一种治疗糖尿病的药物组合物 | |
CN104474099B (zh) | 一种甜茶止咳露及其制备方法 | |
CN1973872B (zh) | 滋阴补肾强身健脑的药物及制备方法 | |
CN108836997A (zh) | 一种用于癌症康复治疗的药物及制备方法 | |
CN104388263A (zh) | 山楂桂圆养生中药酒及制备方法 | |
CN103725587A (zh) | 黄精山楂醋及其生产方法 | |
CN1192789C (zh) | 一种治疗糖尿病的茶及其制备方法 | |
CN102302655B (zh) | 枇杷清痤胶囊 | |
CN112807415A (zh) | 一种温补脾胃的理中茶及其制备方法 | |
CN111870630A (zh) | 一种用于增加抵抗力和免疫力的药物配方及制备工艺 | |
CN116440224B (zh) | 一种中药组合物、制剂及制备方法 | |
CN104922504A (zh) | 治疗动脉粥样硬化的醋饮及制备方法 | |
CN103989938A (zh) | 一种防治糖尿病的壳聚糖组合物及其制备方法 | |
CN103494934A (zh) | 一种无糖型九味补血口服液及其制备方法 | |
CN108929834A (zh) | 铁皮石斛功能性酱香型白酒及其制备方法 | |
CN104825735A (zh) | 补肾保健药酒 | |
CN109106842B (zh) | 一种用于戒烟的药物及其制备方法 | |
CN107213283A (zh) | 一种抗疲劳、平衡阴阳的食药两用中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181120 |